Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Completed Phase 4 Interventional Results available

Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery

NCT03325972
View directory record Official record
Conditions
Chronic Pain
Interventions
Dexmedetomidine, Placebo Saline
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 16, 2026, 2:26 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

NCT00406419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 16, 2026, 2:26 AM EDT
Recruiting Phase 4 Interventional

Magnesium and Cramping

NCT06745388
View directory record Official record
Conditions
Uterine Cramps, Postoperative Pain Management, Hysteroscopy
Interventions
Magnesium sulfate, Ketamine, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

NCT02170337
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
AMG 282, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Santa Monica, California • Aurora, Colorado • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Early Phase 1 Interventional

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

NCT05291286
View directory record Official record
Conditions
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 16, 2026, 2:26 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

NCT03530345
View directory record Official record
Conditions
Complex Regional Pain Syndrome (CRPS)
Interventions
Neridronic acid 100 mg, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 16, 2026, 2:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

NCT01212094
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Rituximab, normal saline
Drug · Other
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ketorolac on Postoperative Pain Reduction in Pediatric Patients with Adenotonsillectomy

NCT05074056
View directory record Official record
Conditions
Adenotonsillar Hypertrophy, Obstructive Sleep Apnea, Sleep-Disordered Breathing, Acute Post Operative Pain
Interventions
Ketorolac
Drug
Lead sponsor
St. Louis University
Other
Eligibility
3 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

NCT04365153
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Canakinumab Injection 600mg, Canakinumab Injection 300mg, Placebos
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02667587
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo
Drug · Radiation · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

NCT00106184
View directory record Official record
Conditions
Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis
Interventions
Rituximab, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
5 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

NCT03827655
View directory record Official record
Conditions
Postoperative Gastrointestinal Dysfunction
Interventions
TAK-954 Placebo, TAK-954
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

NCT01929226
View directory record Official record
Conditions
Inhalational Anthrax
Interventions
ETI-204, Placebo
Biological · Other
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 16, 2026, 2:26 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 16, 2026, 2:26 AM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1

NCT04860960
View directory record Official record
Conditions
Niemann-Pick Disease, Type C1
Interventions
Hydroxypropyl-beta-cyclodextrin, Placebo
Drug
Lead sponsor
Cyclo Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Oakland, California • Jacksonville, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 16, 2026, 2:26 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, IgAN
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
39
States / cities
Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 2:26 AM EDT
Withdrawn Phase 4 Interventional

Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF

NCT00505791
View directory record Official record
Conditions
Heart Failure, Congestive, Dyspnea, Pulmonary Edema
Interventions
Nesiritide
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 16, 2026, 2:26 AM EDT
Terminated Phase 3 Interventional Results available

Study of Rapastinel as Monotherapy in Patients With MDD

NCT03560518
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 75 Years
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients

NCT00606489
View directory record Official record
Conditions
Burns
Interventions
Caldolor, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Orlando, Florida • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Interactive Effects of IV Ethanol and IV Nicotine

NCT01814410
View directory record Official record
Conditions
Healthy
Interventions
Intravenous ethanol placebo plus nicotine infusions, intravenous ethanol 40mg% plus nicotine infusions, intravenous ethanol 100mg% plus nicotine infusions
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 1 Interventional

3BNC117 and 10-1074 in HIV-infected Individuals

NCT02825797
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
3BNC117, 10-1074, Analytical treatment interruption, Placebo
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 1 Interventional Results available

Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

NCT01003691
View directory record Official record
Conditions
Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
Interventions
RN6G, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
24
States / cities
Campbell, California • Los Gatos, California • San Jose, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 16, 2026, 2:26 AM EDT
Completed Phase 2 Interventional Results available

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

NCT01670565
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Belimumab, Mycophenolate Mofetil, Placebo Infusion
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 16, 2026, 2:26 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NCT04832009
View directory record Official record
Conditions
Blood Pressure, Hypertension
Interventions
Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 16, 2026, 2:26 AM EDT